INTRODUCTION
Ovarian cancer is one of the leading cause of mortality due to female genital tract malignancy. 1 Ovarian cancer has emerged as one of the most common malignancy affecting Indian women. The annual percentage of increase in age standardized incidence rates ranged from 0.7% to 2.4%. 2 Gynaecological cancers have increased in India and are estimated to be around 182,602 by the year 2020 constituting about 30% of the total cancers among women in India. Ovarian cancer contributes about 19.8% of the total cases. 3 Risk malignancy index (RMI) is a simple scoring system based on three factors serum CA 125, USG score & menopausal status. It is very useful in predicting a malignant ovarian mass. It is also useful in differentiating malignant from benign ovarian mass. In most of the cases ovarian tumours are diagnosed at a later stage since incidence of onset and progression of this tumour makes early diagnosis difficult.
prognosis and costs involved. On the other hand benign adnexal mass may simply be managed with cystectomy or laparotomy. This is adequate to signify the importance of pre-operative determination of the nature of adnexal mass for optimal and appropriate primary treatment.
Various combined methods of evaluating the risk of ovarian cancer have been proposed. 4 The scoring methods based on menopausal status, ultrasonographic examination and serum CA-125 yield much better results than the earlier mentioned individual parameters. Risk of Malignancy Index (RMI) is calculated with a simplified regression equation obtained from the product of menopausal status score (M), ultrasonographic score (U) and absolute value of serum CA-1255. RMI was originally developed by Jacobs et al at 1990. It is known as RMI-1 and that developed by Tingulstad et al with slight modification in score value of menopausal status and ultrasound score is RMI-2. 5 It was modified to RMI-3 in 1999. 6 RMI is a simple scoring system which can be applied in less specialized centres. In many studies, cut off value of Risk of malignancy index was taken as 200 but according to RCOG guidelines, 7 the cut off level is 250 for predicting malignancy since higher cut off level increased the detection rate of true negative cases.
Keeping this in mind, we have considered cut off level 250 for predicting malignancy in present study. [7] [8] [9] This study was aimed to assess the validity of RMI in clinically diagnosed ovarian masses in pre-operative women & comparing it with the validity of individual constituent parameter of RMI.
METHODS
This was an observational study conducted at department of obstetrics and gynaecology, GMCH Aurangabad from October 2012 to 2014 with sample size of 102 cases with clinical diagnosis of ovarian mass admitted for laparotomy.
Inclusion criteria
1. Women with clinically restricted ovarian mass of any age group. 2. For premenopausal women, criteria for ovarian masses are its size more than 8 cm and for postmenopausal women size more than 5 cm. 3. Post-menopausal status defined as more than 1 year of amenorrhea or, women who underwent hysterectomy.
Exclusion criteria
1. Women having ovarian tumor with other condition like endometriosis, fibroid, pregnancy, PID, women in menstruating phase and associated with concurrent malignancy.
2. Patients who were unfit for major surgery, inoperable cases, previous major pelvic surgery. 3. Intra-operatively, any other mass than ovary was also excluded from study.
Total 102 women with clinically diagnosed as ovarian mass who were admitted for laparotomy in a tertiary care hospital, after fulfilling the inclusion and exclusion criteria were studied. Detailed clinical history was taken pertaining to their age, parity, socioeconomic status along with symptoms. Clinical examination was done. USG (abdomen + pelvis) performed with full bladder technique with 3-5 MHz probe frequency.
Ultrasound scoring
Ultrasound score (U) was based on one point for each of the following, Ultrasound scoring were recent ones done within two weeks prior to laparotomy.
Serum CA-125 level estimation
Peripheral venous blood sample (5 ml) was drawn from each patient, prior to surgery for the estimation of serum CA-125 level. Serum CA-125 level was determined by radioimmunoassay (MINIVEDAS CA-125 MACHINE). SERUM CA 125 >200 IU/ml in premenopausal & >35 IU/ml in postmenopausal women were considered together as high risk of ovarian malignancy.
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Menopausal Scoring (M)
For premenopausal woman score 1 was given, for postmenopausal woman score 3 was given. RMI calculated for each subject by multiplying USG score, menopausal score and Serum CA125 level value. RMI = U × M × Serum CA-125 level 12 Operative findings during laparotomy of all cases were obtained. It was made sure that the operated specimen or tissue was immersed in formalin solution and sent for histopathological examination; ascitic fluid or peritoneal washing was sent for cytological examination in a sterile syringe immediately. The cytological and histopathological examinations were all done in, department of Pathology. Histopathological diagnosis was considered as gold standard for defining outcome.
Interpretation of risk malignancy index (RMI)
If the score < 25, it was considered as low risk, If the score 25-250, it was considered as, moderate risk & If the score > 250, it was considered as high risk.
Statistical analysis was done with appropriate test at the end of the study. 7 Results of RMI were validated against histopathologically confirmed lesions. Table 1 shows baseline characteristics of study group. 
RESULTS
DISCUSSION
Risk of malignancy index is the integration of serum CA-125, menopausal status and USG findings. In the present study, the cut off level of RMI is taken as 250.This scoring was more closer to Zinatossadat Bouzari et al, 13 who used 265 as cut off .In the present study sensitivity, specificity, PPV & NPV of RMI was found to be 85.71%, 85.07%, 75%, 91.93% respectively. Similar statistical significance was observed by Ismail Kestane et al 14 and Zinatossadat Bouzari et al. 13 In the present study, out of 102 clinically diagnosed ovarian masses, 7 cases were noted with lower RMI (i.e.<250 ) which turned out to be malignant on histopathology. This gave the false negative rate of 11.11%. It was also noted that in these 7 cases, Serum CA 125 was within normal range. This could be explained on the basis of histopathology of individual cases. Out of these seven cases, three cases were of mucinous cystadenocarcinomas & two were dysgerminomas, one was immature teratoma & one case of sex cord stromal tumor (steroidal cell tumor). This could be because of serum CA-125 has limited role in recognizing mucinous cystadenocarcinomas. Similar findings were noted by Ismail Kestane et al. 14 Immuno histochemical studies have demonstrated Serum CA-125 expression to be a feature of cells derived from embryonal coelomic epithelium and mullerian duct. 15 Serum CA-125 levels usually rise in epithelial tumors whereas levels may not increase in non-epithelial tumor like dysgerminoma, immature teratoma , sex cord stromal tumor.
In the present study, USG score 0 was seen in 5.8% cases which resulted into RMI zero in those cases. Hence USG score 0 was major factor to contribute to more false negative results in RMI. This USG score 0 was excluded by Taherah Ashrafgangooei et al, 16 M.A. Suuiqing et al, 17 Ismail Kestane et al 14 so as to decrease the false negative results. These authors included the USG score 1 & 3 only to calculate the RMI.
In the present study, menopausal status had a sensitivity of 60% & specificity of 71.64%. Hence menopausal status could be a weak constituent of RMI. Taherah Ashrafgangooei et al 16 had shown higher specificity of 93.18% .This discrepancy in the present study was due to the proportion of sample size which included a larger number of pre-menapausal women as compared to postmenopausal (86.3%).
Comprehensive index overcomes the false positive result obtained when using a single parameter like menopausal status or serum CA-125 or USG alone. RMI also increases the sensitivity & specificity in the pre-operative diagnosis of ovarian mass.
If patients with ovarian cancers are diagnosed at early stage (I or II), the cure rate could be as high as 80-90% and the mortality rate could decrease up to 50%. Hence, this method of diagnosis is of great importance for prediction of the prognosis. Selective referral of patients with high risk of malignancy to specialized oncology centers is of paramount importance. The primary cytoreductive surgery has a great role in deciding the prognosis of ovarian cancers.
CONCLUSIONS
RMI is simple, valuable, highly reliable & clinically applicable scoring system, in pre-operative evaluation of ovarian mass. RMI is very useful in differentiating malignant from benign lesion.
The present study demonstrates that the validity of RMI is higher as compared to validity of individual parameters and hence, has a better discriminating power to diagnose malignancy.
Simplicity and applicability of the method in the primary evaluation of patients with pelvic masses, makes it a good option in daily clinical gynaecological practice.
